Daphne H Schoenmakers,Sibren van den Berg,Lonneke Timmers,Laura A Adang,Tobias Bäumer,Annet Bosch,Marc van de Casteele,Mareen R Datema,Hanka Dekker,Conan Donnelly,Mariëtte H E Driessens,Holm Graessner,Valerie Greger,Tala Haddad,Günter U Höglinger,Hannerieke van den Hout,Carla Jonker,Mirjam Langeveld,Laurie J Lambert,Eileen Neacy,Marc Nieuwland,Thomas Klockgether,Marjo S van der Knaap,Andri Papadopoulou,Kelly Plueschke,Sanne van Rijn,Noa Rosenberg,Elise F Saunier-Vivar,Bruna Dos Santos Vieira,Carla E M Hollak,Wim G Goettsch,Nicole I Wolf

Abstract:Progress in genetic diagnosis and orphan drug legislation has opened doors to new therapies in rare neurogenetic diseases (RNDs). Innovative therapies such as gene therapy can improve patients' quality of life but come with academic, regulatory, and financial challenges. Registries can play a pivotal role in generating evidence to tackle these, but their development requires multidisciplinary knowledge and expertise. This study aims to develop a practical framework for creating and implementing patient registries addressing common challenges and maximizing their impact on care, research, drug development, and regulatory decision making with a focus on RNDs. A comprehensive 3-step literature and qualitative research approach was used to develop the framework. A qualitative systematic literature review was conducted, extracting guidance and practices leading to the draft framework. Subsequently, we interviewed representatives of 5 established international RND registries to add learnings from hands-on experiences to the framework. Expert input on the draft framework was sought in digital multistakeholder focus groups to refine the framework. The literature search; interviews with 5 registries; and focus groups with patient representatives (n = 4), clinicians (n = 6), regulators, health technology assessment (HTA) bodies and payers (n = 7), industry representatives (n = 7), and data/information technology (IT) specialists (n = 5) informed development of the framework. It covers the interests of different stakeholders, purposes for data utilization, data aspects, IT infrastructure, governance, and financing of rare disease registries. Key principles include that data should be rapidly accessible, independent, and trustworthy. Governance should involve multiple stakeholders. In addition, data should be highly descriptive, machine-readable, and accessible through a shared infrastructure and not spread over multiple isolated repositories. Sustainable and independent financing of registries is deemed important but remains challenging because of a lack of widely supported funding models. The proposed framework will guide stakeholders in establishing or improving rare disease registries that fulfill requirements of academics and patients as well as regulators, HTA bodies, and commercial parties. There is a need for more clarity regarding quality requirements for registries in regulatory and HTA context. In addition, independent financing models for registries should be developed, as well as well-defined policies on technical uniformity in health data.

Increase transparency and reproducibility of real‐world evidence in rare diseases through disease‐specific Federated Data Networks

Real-World Evidence Gathering in Oncology: The Need for a Biomedical Big Data Insight-Providing Federated Network

Use of real‐world evidence in regulatory decisions for rare diseases in the United States—Current status and future directions

A rare partnership: patient community and industry collaboration to shape the impact of real-world evidence on the rare disease ecosystem

Framework for Multistakeholder Patient Registries in the Field of Rare Diseases: Focus on Neurogenetic Diseases

The EuRRECa Project as a Model for Data Access and Governance Policies for Rare Disease Registries That Collect Clinical Outcomes

Data silos are undermining drug development and failing rare disease patients

An overview of Real-World Data infrastructure for cancer research

Recommendations for Improving the Quality of Rare Disease Registries

Use of Real-World Data and Real-World Evidence in Rare Disease Drug Development: A Statistical Perspective

Natural History and Real‐World Data in Rare Diseases: Applications, Limitations, and Future Perspectives

Advancing the Real-World Evidence for Medical Devices through Coordinated Registry Networks

Establishing Patient Registries for Rare Diseases: Rationale and Challenges

Real-world evidence for coverage determination of treatments for rare diseases

[The role of real-world evidence for the study of rare diseases epidemiology and the post-marketing evaluation of orphan drugs]

From real world data to real world evidence to improve outcomes in neuro-ophthalmology

The importance of international collaboration for rare diseases research: a European perspective

The Rare Diseases Clinical Research Network: a model for clinical trial readiness

Reality check: Real-world evidence to support therapeutic development in hematologic malignancies

Generating Evidence from Expanded Access Use of Rare Disease Medicines: Challenges and Recommendations

Secondary use of patient data within decentralized studies using the example of rare diseases in Germany: A data scientist's exploration of process and lessons learned